Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/tratamiento farmacológico , Factor VIII/uso terapéutico , Fibrinógeno/uso terapéutico , Factor VIII/química , Factor VIII/historia , Fibrinógeno/química , Fibrinógeno/historia , Liofilización , Congelación , Infecciones por VIH/virología , Historia del Siglo XX , Humanos , Inactivación de VirusRESUMEN
The possibility of alloimmunization in patients receiving protein replacement therapy depends on (at least) three risk factors, which are necessary concomitantly but insufficient alone. The first is the degree of structural difference between the therapeutic protein and the patient's own endogenous protein, if expressed. Such differences depend on the nature of the disease mutation and the pre-mutation endogenous protein structure as well as on post-translational changes and sequence-engineered alterations in the therapeutic protein. Genetic variations in the recipients' immune systems comprise the second set of risk determinants for deleterious immune responses. For example, the limited repertoire of MHC class II isomers encoded by a given person's collection of HLA genes may or may not be able to present a 'foreign' peptide(s) produced from the therapeutic protein - following its internalization and proteolytic processing - on the surface of their antigen-presenting cells (APCs). The third (and least characterized) variable is the presence or absence of immunologic 'danger signals' during the display of foreign-peptide/MHC-complexes on APCs. A choice between existing therapeutic products or the manufacture of new proteins, which may be less immunogenic in some patients or patient populations, may require prior definition of the first two of these variables. This leads then to the possibility of developing personalized therapies for disorders due to genetic deficiencies in endogenous proteins, such as haemophilia A and B. [Correction made after online publication 11 July 2011: several critical corrections have been made to the abstract].
Asunto(s)
Factor VIII , Hemofilia A , Economía Farmacéutica , Factor VIII/genética , Factor VIII/inmunología , Factor VIII/uso terapéutico , Predisposición Genética a la Enfermedad , Hemofilia A/tratamiento farmacológico , Hemofilia A/genética , Hemofilia A/inmunología , Antígenos de Histocompatibilidad Clase II/inmunología , Humanos , Tolerancia Inmunológica/genética , Isoanticuerpos/inmunología , Factores de RiesgoAsunto(s)
Hemofilia A/genética , Hemofilia B/genética , Familia , Femenino , Tamización de Portadores Genéticos , Humanos , MasculinoRESUMEN
Mosaicism may affect the haemophilia phenotype. Well-known instances include chromosomal mosaicism due to aneuploidy and pseudo-mosaicism due to varying patterns of X-chromosome inactivation. Chromosomal mosaicism in a chimera is a potential source of phenotypic variation. Gene mosaicism is commonplace. Its pattern and effect depend on the stage of development at which a mutation occurs. Proven or possible genetic mosaicism is an important consideration when predicting the likelihood of transmission of haemophilia to a future generation.
RESUMEN
Some mosaic conditions may affect the haemophilia phenotype. Well-known instances include chromosomal mosaicism because of aneuploidy and pseudo-mosaicism because of varying patterns of X-chromosome inactivation. Chromosomal mosaicism in a chimera is a potential source of phenotypic variation. Gene mosaicism is commonplace. Its pattern and effect depend on the stage of development at which a mutation occurs. Proven or possible genetic mosaicism is an important consideration when predicting the likelihood of transmission of haemophilia to a future generation. A mosaic is an individual who has two or more cell lines, genetically different with regard to chromosomes or genes. As techniques improve and studies accumulate, mosaics are being found to be more common than hitherto believed. Some mosaic conditions may affect the phenotype of haemophilia in males and of the carrier state in females. Cells may be mosaic with regard to chromosomes, as in some instances of aneuploidy, and in chimeras, and in females owing to the pattern of X-chromosome inactivation. Cells may be mosaic with regard to new gene mutations. The pattern of mosaicism depends upon the stage in embryogenesis or in germ-cell formation in which the mutation arose.
Asunto(s)
Enfermedades Genéticas Ligadas al Cromosoma X/genética , Predisposición Genética a la Enfermedad/genética , Hemofilia A/genética , Mosaicismo , Quimera/genética , Femenino , Humanos , Masculino , Fenotipo , Inactivación del Cromosoma X/genéticaRESUMEN
In an analysis of 804 haemophilia pedigrees, mild to moderate haemophilia A or B was found to be clearly familial in 70% of cases, severe haemophilia B in 57% of cases and severe haemophilia A in 45% of cases. The rest of the patients were 'sporadic' i.e., either isolated cases or brothers in the first affected sibship. In sporadic families, 88% of mothers but only 19% of maternal grandmothers had the relevant mutation in their white blood cells. Among patients with familial haemophilia, half the patients with mild haemophilia and those with severe haemophilia B had a direct male ancestor with haemophilia, but only 28% of patients with severe haemophilia A had such a progenitor.
Asunto(s)
Hemofilia A/epidemiología , California/epidemiología , Portador Sano , Femenino , Hemofilia A/genética , Hemofilia B/epidemiología , Hemofilia B/genética , Humanos , Masculino , Mosaicismo , Mutación , Linaje , Prevalencia , Estudios RetrospectivosAsunto(s)
Síndrome de Inmunodeficiencia Adquirida/transmisión , Transfusión de Componentes Sanguíneos/efectos adversos , Hemofilia A/terapia , Hepatitis Viral Humana/transmisión , Reacción a la Transfusión , Síndrome de Inmunodeficiencia Adquirida/sangre , Donantes de Sangre/estadística & datos numéricos , Hemofilia A/sangre , Hepatitis Viral Humana/sangre , Humanos , Selección de Paciente , PlasmaféresisRESUMEN
Safety from transmission of infections through plasma-derived clotting factor concentrates is assured by improved donor screening, serological testing of individual donations and direct viral testing of small plasma pools. Modern viral-inactivation techniques are highly effective. Recombinant concentrates stabilized in human albumin are being superaeded by those with other stabilizers. Recently reported discrepancies between estimates of concentrate potency from in vitro assays versus in vivo recovery, depending upon type of assay and reference standard used, are not fully resolved.
Asunto(s)
Factor IX/uso terapéutico , Factor VIII/uso terapéutico , Hemofilia A/tratamiento farmacológico , Factor IX/efectos adversos , Factor IX/normas , Factor VIII/efectos adversos , Factor VIII/normas , Humanos , Equivalencia Terapéutica , Virosis/prevención & control , Virosis/transmisiónRESUMEN
Research subjects in developing countries may be especially vulnerable to exploitation. Scrupulous care should be taken to maintain the basic principles of ethical trial conduct: the right of participants to make their own informed decisions, a favorable balance of benefit to risk, good trial design, candour about results, and, above all, use of honourable investigators. Involvement of local participants in planning a trial helps ensure both culturally-sensitive protocols and consents and also maximum benefit to patients and to local research infrastructure.
Asunto(s)
Ensayos Clínicos como Asunto/ética , Países en Desarrollo , Hemofilia A/terapia , Ensayos Clínicos como Asunto/normas , Ética Clínica , HumanosRESUMEN
Porcine factor VIII (pFVIII) is an effective haemostatic treatment for bleeding in selected patients with FVIII inhibitors. Its use is sometimes associated with a transient fall in platelet count and transfusion reactions, the risk of which may be related to the rate of administration. Theoretical considerations suggest that the administration of pFVIII by continuous infusion should be effective, and could have pharmacokinetic advantages that lead to an improvement in the side-effect profile. The results of a retrospective survey of continuous infusion of pFVIII with respect to clinical safety and efficacy are reported. Porcine FVIII stability and microbiological studies are included. It is concluded that pFVIII given by continuous infusion is safe and effective. The risk of transfusion reactions and fall in platelet count appears to be reduced, compared with bolus administration. Stability studies showed that pFVIII activity declined at room temperature, most rapidly in the dilute solution (5-10 U mL(-1)). More concentrated mixtures showed acceptable stability for up to 24 h using a variety of infusion devices. Various concentrations of pFVIII did not support the growth of Escherichia coli or Staphylococcus aureus. These observations suggest that the porcine factor is suitable for continuous infusion (CI).
Asunto(s)
Factor VIII/administración & dosificación , Adolescente , Adulto , Animales , Bacterias/crecimiento & desarrollo , Niño , Preescolar , Seguridad de Productos para el Consumidor , Recolección de Datos , Estabilidad de Medicamentos , Factor VIII/normas , Hemofilia A/complicaciones , Hemofilia A/tratamiento farmacológico , Humanos , Lactante , Infusiones Parenterales/efectos adversos , Infusiones Parenterales/métodos , Infusiones Parenterales/normas , Porcinos , Equivalencia TerapéuticaRESUMEN
Two germline retrotransposition mutations of recent origin were observed in 727 independent mutations (0.28%) in the human factor IX gene (F9) of patients with hemophilia B: 1) a 279 bp insertion in exon H originating from an Alu family of short interspersed elements not previously known to be active and, 2) a 463 bp insertion in exon E of a LINE1 element originating in the maternal grandmother. If the rates of recent germline mutation in F9 are typical of the genome, a retrotransposition event is estimated to occur somewhere in the genome of about one in every 17 children born. Analysis of other estimates for retrotransposition frequency and overall mutation rates suggests that the actual rate of retrotransposition is likely to be in the range of one in every 2.4 to 28 live births.
Asunto(s)
Factor IX/genética , Retroelementos/genética , Elementos Alu/genética , Secuencia de Aminoácidos , Secuencia de Bases , ADN/genética , Frecuencia de los Genes , Hemofilia B/genética , Humanos , Datos de Secuencia Molecular , Mutagénesis Insercional , Mutación , Homología de Secuencia de Ácido NucleicoRESUMEN
A multicentre retrospective survey was conducted to assess the efficacy and side-effect profile of porcine factor VIII (pFVIII:C) given by continuous infusion (CI) to patients with congenital haemophilia A and inhibitors. Twenty-nine episodes in 18 patients were treated by CI of pFVIII:C. Efficacy was graded as good in 79% of infusions and fair in 17%. There was a failed response in only one episode. Fourteen percent of patients experienced transfusion reactions with bolus doses, but no reactions were observed in patients given CI. There were no severe reactions. All the reactions resolved following interruption of the infusion and administration of steroids. Premedication did not prevent reactions. In this series the median decrease in platelet count after bolus injection of pFVIII:C was -67 X 10(9) L(-1) compared with a median decrease of -2 x 109 L(-1) during the course of CI, thus, continuous infusion of pFVIII:C appears to have less effect on platelet count than bolus injection. An anamnestic response was associated with 77% of infusions. This high rate of anamnesis reflects patient selection, in that they were all known to have high-level high-responding FVIII inhibitors with cross-reactivity to pFVIII. After reconstitution, the pFVIII:C showed little loss in factor VIII activity in solution over a 24-h period. We conclude that pFVIII:C may be effectively administered by CI to patients with haemophilia A and high-responding FVIII inhibitors. CI is the probably the mode of administration of choice for intensive replacement therapy with pFVIII.
Asunto(s)
Factor VIII/administración & dosificación , Hemofilia A/tratamiento farmacológico , Infusiones Parenterales/normas , Isoanticuerpos/sangre , Adolescente , Adulto , Animales , Niño , Preescolar , Evaluación de Medicamentos , Factor VIII/inmunología , Factor VIII/toxicidad , Hemofilia A/complicaciones , Hemorragia/tratamiento farmacológico , Hemorragia/etiología , Humanos , Lactante , Recuento de Plaquetas , Estudios Retrospectivos , Porcinos , Resultado del TratamientoAsunto(s)
Trastornos de las Proteínas de Coagulación/terapia , Factores de Coagulación Sanguínea/inmunología , Factores de Coagulación Sanguínea/normas , Factores de Coagulación Sanguínea/uso terapéutico , Trastornos de las Proteínas de Coagulación/diagnóstico , Trastornos de las Proteínas de Coagulación/genética , Atención Dental para Enfermos Crónicos , Manejo de la Enfermedad , Femenino , Pruebas Genéticas , Hemofilia A/complicaciones , Hemofilia A/genética , Hemofilia A/terapia , Humanos , Infecciones/etiología , Infecciones/terapia , Artropatías/etiología , Artropatías/terapia , Masculino , EmbarazoRESUMEN
Two-base substitutions at each of two nucleotides in the factor IX gene (F9), but not part of CpG dinucleotides, were recently reported in a small population sample collected in Mexico, a significant observation of recurrent sites ("hotspots") of mutation (P=0.00005). When these new data were combined with previously collected mutation data into two progressively larger and inclusive Latin American samples, additional mutations were observed at one recurrent site, nucleotide 17747, and an additional recurrent nucleotide was observed such that the recurrent nucleotides in these larger samples were also significant (P=0.0003 and 0.0003). In contrast, in three non-Latin American control samples, there was at most only one nucleotide that recurred only once, most likely a chance recurrence (P>/=0.5). When the significance of substitutions was analyzed at each recurrent nucleotide individually, nucleotide 17747 was shown to be a significant recurrent nucleotide by itself in all the Latin American population samples (P=0.02). Furthermore, a standard statistical comparison of mutation frequencies in the previously collected data alone confirmed that the frequency of mutation at nucleotide 17747 is significantly higher in Latin Americans than in all other populations combined (P=0.01). Thus, nucleotide 17747 is a germline mutation hotspot in F9 specific to Latin American populations. This may be the first evidence for population-specific effects on germline mutation that causes human genetic disease. The significance of the observed recurrent sites was analyzed using new software called Hotspot Detector which is capable of detecting significant recurrent sites in small samples, extending the sensitivity of F9 as a human germline mutagen test. Hotspot Detector uses a Monte-Carlo simulation method that was validated by comparing its results with those from an exact probability formula derived from statistical theory.
Asunto(s)
Islas de CpG/genética , Factor IX/genética , Mutación de Línea Germinal/genética , Programas Informáticos , Femenino , Variación Genética , Genética de Población , Humanos , Masculino , México/etnología , Recombinación Genética/genéticaAsunto(s)
Factor VIII/administración & dosificación , Hemorragia/tratamiento farmacológico , Factor VIII/inmunología , Hemofilia A/complicaciones , Hemofilia A/tratamiento farmacológico , Hemorragia/complicaciones , Humanos , Isoanticuerpos/sangre , Isoanticuerpos/efectos de los fármacos , Guías de Práctica Clínica como AsuntoRESUMEN
Pharmacokinetic studies in haemophilia B have found in vivo recovery of FIX (FIX) to be uniformly lower than the factor VIII recovery in haemophilia A. We hypothesized that this lower recovery could result from rapid binding to high-affinity receptors on platelets and endothelium. To test this hypothesis, we evaluated the kinetics of FIX activity and protein in haemophilia B patients. Twelve patients were enrolled in a double dosing, crossover study with two high-purity FIX concentrates, AlphaNine SD and MonoNine. Subjects were given 40 U kg-1 of FIX concentrate and blood samples were taken at 15, 30, and 60 min. A second infusion of 40 U kg-1 was given after the 60 min blood sample and further blood samples removed at 15, 60, 120, and 360 min after the second dose. Patients were infused with the alternate concentrate at least 7 days later. Plasma samples were assayed for FIX activity by coagulation assay and antigen by RIA. FIX antigen in the infused concentrates was measured and quantified as microg U-1. There was no difference between the two FIX concentrates (AlphaNine vs. MonoNine) in the initial (15 min) activity (57% +/-1 19% vs. 53% +/-1 12%) and antigen (62% +/-1 16% vs. 55% +/-1 19%) recoveries. Recoveries after the second FIX dose were not statistically different than those observed after the first FIX dose. In one patient, a doubling of the initial infusion dose did not increase FIX recovery after the second FIX dose. However, the recovery of FIX antigen was significantly greater than the recovery of FIX activity and the differences became more significant in the post-15 min samples. We calculated a ratio of plasma FIX antigen to FIX activity in microg U-1. Average antigen to activity ratio increased from 5.8 +/-1 1.9 microg U-1 at 15 min to 7.1 +/-1 2.2 microg U-1 at 60 min. At 420 min the ratio increased to 9.3 +/-1 2.4 microg U-1. Although these studies failed to demonstrate a significant FIX receptor pool, they did demonstrate a phenomenon of progressive loss of biologic activity of the FIX protein after infusion of FIX concentrates.
Asunto(s)
Factor IX , Hemofilia B/tratamiento farmacológico , Plaquetas/inmunología , Plaquetas/metabolismo , Estudios Cruzados , Endotelio Vascular/inmunología , Endotelio Vascular/metabolismo , Epítopos/inmunología , Factor IX/administración & dosificación , Factor IX/inmunología , Factor IX/farmacocinética , Hemofilia B/inmunología , Humanos , Infusiones Intravenosas , Receptores de Superficie Celular/metabolismoRESUMEN
Fifty-eight previously treated haemophilic subjects were treated exclusively with the recombinant FVIII (rFVIII-KOGENATE) produced by Bayer Corporation (Berkeley, CA) in an international multicentre prospective study of more than 5 years duration. Fifty-four of the 58 had severe haemophilia (< 2% FVIII) and four had moderate haemophilia (2-5% FVIII); 23/58 (40%) were seropositive for HIV, while 35/58 (60%) were HIV seronegative. Patients were monitored for safety and efficacy over a median period of 4.7 years (range 0.9-5.9 years) and received 17 922 infusions totalling 25.7 million units of rFVIII. Of 7107 bleeding episodes reported in home diaries, 5831 (82%) required only one treatment with rVIII. Twenty-five invasive surgical procedures in 17 patients, including eight joint replacements, were successfully accomplished and 13 serious bleeding episodes in eight patients were successfully treated. FVIII recovery performed on 885 occasions using 39 different lots of rFVIII showed mean incremental recovery of 2.48% IU-1 kg-1 (+/- 0.64). Adverse events were associated with 42 infusions (0.2%); none caused discontinuation of therapy. Immunological parameters remained stable in HIV-seronegative subjects treated with rFVIII; a small decrease in CD4 counts was noted in HIV-seropositive individuals (mean - 37.2 cells mm-3 yr-1). No de novo formation of inhibitors to FVIII was noted; and no clinical allergic reactions occurred to murine or hamster proteins. These conclusions from the longest monitored safety study ever performed for a haemophilia treatment product (with more than 5 years of observation) confirm previous interim study reports that rFVIII is well tolerated over the long-term, has biological activity comparable to that of plasma-derived FVIII, and is safe and efficacious for the treatment of haemophilia A.
Asunto(s)
ADN Recombinante/genética , Factor VIII/uso terapéutico , Hemofilia A/tratamiento farmacológico , Servicios de Atención de Salud a Domicilio , Adolescente , Adulto , Anciano , Animales , Formación de Anticuerpos , Niño , Preescolar , Cricetinae , Factor VIII/genética , Factor VIII/farmacocinética , Seropositividad para VIH , Hemofilia A/metabolismo , Humanos , Inmunidad Celular , Lactante , Ratones , Persona de Mediana Edad , Monitorización Inmunológica , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéuticoRESUMEN
We report the second confirmed case of the haemophilia B 'Brandenberg' phenotype. At the time of testing, patient HB530 was a 17-year-old post-puberty male with a persistent, clinically severe bleeding disorder and markedly reduced plasma procoagulant factor IX activity (< 1%). Sequencing studies revealed a G-->A transition at bp - 26 within the promoter region of the factor IX gene. This case report confirms the observation that not all patients with promoter mutations improve after puberty and supports the hypothesis that bp - 26 is a critical binding site within the factor IX gene promoter region for both constitutive as well as androgen-inducible transcription factors.